Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

About this update from Tetra Bio-pharma Inc.

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir Canada NewsWire MONTREAL, Dec. 6, 2022 The combination of ARDS-003 and Favipiravir presents viable treatments against viral infections. Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival in younger patients.Tetra and Cellvera to develop an orally administered treatment, ARDS-003, in combination with Favipiravir.MONTREAL, Dec. 6, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster. Results from the study demonstrate that Tetra's investigational therapeutic, ARDS-003, which contains the active pharmaceutical ingredient Onternabez, acts against various ARDS and Sepsis targets, such as IL-6 and IL-8. Onternabez plays an important role in mitigating the inflammatory response in various targets of inflammatory conditions. Favipiravir acts against different SARS-CoV-2 targets, such as spike glycoprotein and nucleoprotein.  The interaction between Favipiravir and Onternabez against SARS-COV-2 yields a positive Molecule Synergy probability which is considered significant and justifies the combination of the two drugs to create a new therapeutic that is expected to be beneficial to increase treatment efficacy and reduce the duration of disease. Favipiravir can control the source of infection. Onternabez would contribute to the antiviral efficacy and can control th...

View stock analysis, news, and events for Tetra Bio-pharma Inc.